Analysis of more than 200 studies involving more than 20,000 patients revealed that the expression of EGFR was also associated with reduced recurrence-free survival in patients with head and neck, ovarian, cervical, bladder and oesophageal cancers. This evidence concerns the gene EGFR and carcinoma of esophagus.